VITALISScETM includes patients with elevated levels of CRP, ESR or KL-6, indicating active inflammation or progressive ILD.33, –35 By including these criteria, the VITALISScETM study is enriched for patients who are potentially at risk for disease progression. The gene discussed is CRP; the disease is interstitial lung disease.